News

EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Consilium1h
Council and Parliament agree on simplified and more efficient handling of chemical assessment data
The OSOA package creates a common platform that integrates existing databases and offers a 'one-stop shop' for chemical data from EU agencies and the Commission. It enables knowledge sharing from one ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Ozempic linked to rare eye disorder according to European regulator
Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...
Medical Dialogues2d
Diabetes and Weight-Loss Drug Semaglutide Linked to Rare Eye Condition: European Medical Agency
Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
India Today6d
European drugs regulator flags rare eye risk with Ozempic use
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Consilium8d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...
Dermatology Advisor1d
European Atopic Eczema Guidelines Update Includes New, Expanded Drug Approvals
The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...
The Manila Times10d
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results ...